Compare GIS & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GIS | RPRX |
|---|---|---|
| Founded | 1866 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.5B | 22.0B |
| IPO Year | 2003 | 2020 |
| Metric | GIS | RPRX |
|---|---|---|
| Price | $31.94 | $55.10 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 5 |
| Target Price | $42.07 | ★ $51.40 |
| AVG Volume (30 Days) | ★ 9.4M | 3.2M |
| Earning Date | 03-18-2026 | 05-06-2026 |
| Dividend Yield | ★ 7.08% | 1.90% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.56 | 0.67 |
| Revenue | $2,037,800,000.00 | ★ $2,378,193,000.00 |
| Revenue This Year | N/A | $38.63 |
| Revenue Next Year | N/A | $4.73 |
| P/E Ratio | ★ $9.04 | $82.04 |
| Revenue Growth | 4.11 | ★ 5.06 |
| 52 Week Low | $31.85 | $33.37 |
| 52 Week High | $55.19 | $55.86 |
| Indicator | GIS | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 30.30 | 65.49 |
| Support Level | N/A | $35.35 |
| Resistance Level | $34.62 | N/A |
| Average True Range (ATR) | 0.88 | 1.14 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 0.54 | 83.21 |
General Mills is a global packaged-food company that produces snacks, cereal, convenient meals, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Pillsbury, Betty Crocker, Blue Buffalo, and Haagen-Dazs. In fiscal 2025, 81% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. Although most of General Mills' products are sold through retail stores to consumers, the company also sells products to the foodservice channel and the commercial baking industry.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.